Chandrasekhar 2012: The Foundational Cortisol RCT
The 2012 study by Chandrasekhar, Kapoor, and Anishetty in the Indian Journal of Psychological Medicine is the most-cited randomized controlled trial of ashwagandha for stress and cortisol. It established the KSM-66 extract as the clinical reference standard for this application.
Design: 64 adults with a history of chronic stress, randomized to KSM-66 ashwagandha root extract 300mg twice daily (600mg/day total) or placebo for 60 days. Double-blind, placebo-controlled. Primary endpoints: Perceived Stress Scale (PSS), General Health Questionnaire (GHQ-28), Depression Anxiety Stress Scale (DASS), serum cortisol, and safety markers including liver function tests.
Results at 60 days:
- Serum cortisol: −27.9% in ashwagandha group vs. −7.9% placebo (significant between-group difference, p<0.0001)
- PSS score: −44.0% vs. −5.5% placebo
- GHQ-28 (general health): −68.1% vs. −10.5% placebo
- DASS anxiety subscale: −75.6% vs. −10.7% placebo
- Food cravings (FCQS): −23.0% vs. −4.7% placebo
- Safety: No serious adverse events; liver function tests normal throughout; mild GI discomfort in 5/32 ashwagandha subjects vs. 4/32 placebo (no significant difference)
The magnitude of cortisol reduction (27.9%) is clinically notable. Chronically elevated cortisol contributes to: immune suppression, visceral fat accumulation, hippocampal neuronal atrophy, insulin resistance, and disrupted sleep architecture. A 28% reduction in serum cortisol represents meaningful physiological impact on all downstream pathways.
Withanolides: The Active Compounds and Their Mechanism
Ashwagandha (Withania somnifera, family Solanaceae) contains over 40 withanolides — steroidal lactones unique to the genus. The primary bioactive withanolides include withaferin A, withanolide D, withanolide A, and withanone. Their concentrations in the root are low in raw plant material (0.1–0.5%) but concentrated 10–100× in standardized extracts.
HPA axis mechanism: The hypothalamic-pituitary-adrenal (HPA) axis is the primary stress response system. Under chronic stress, persistent CRH (corticotropin-releasing hormone) from the hypothalamus → ACTH from the pituitary → cortisol from the adrenal cortex becomes dysregulated — the negative feedback loop (where rising cortisol should suppress CRH/ACTH) becomes blunted through glucocorticoid receptor downregulation in the hypothalamus.
Withanolides act at multiple points in this cascade:
- Glucocorticoid receptor (GR) modulation: Withaferin A has structural similarity to cortisol precursors and interacts with GR. Evidence suggests withanolides restore GR sensitivity in the hypothalamus, improving negative feedback and reducing chronic HPA overdrive — the mechanism most consistent with observed cortisol reduction without complete cortisol blockade
- HSP90 inhibition: Withaferin A covalently binds Hsp90, a chaperone protein required for GR trafficking and function; this modulates GR nuclear translocation and downstream cortisol signaling in target tissues
- GABA-A receptor potentiation: Sitoindosides (glycowithanolides) enhance GABAergic tone — relevant to anxiolytic effects independent of cortisol; explains why ashwagandha's anxiolytic effect (−75% DASS anxiety) exceeds what cortisol reduction alone would predict
- Mitochondrial protection: Withanolide A and D protect against oxidative stress in neuronal mitochondria; withanolide D shows neuroprotective effects in Alzheimer's models (promotes dendrite regrowth; Kuboyama 2005)
Testosterone and Muscle Performance: Wankhede 2015
Wankhede et al. 2015 (Journal of the International Society of Sports Nutrition, N=57 resistance-trained men, double-blind RCT) tested KSM-66 at 300mg twice daily vs. placebo for 8 weeks alongside a standardized resistance training program.
Results:
- Serum testosterone: +17% in ashwagandha group vs. −2% placebo (significant)
- Bench press 1RM: +18.8 kg vs. +10.9 kg placebo (significant)
- Leg extension 1RM: +16.9 kg vs. +8.1 kg placebo (significant)
- Muscle recovery (DOMS): significantly reduced in ashwagandha group
- VO₂max: +18.3% vs. +8.4% placebo
The testosterone mechanism is likely indirect: cortisol suppresses testosterone production at the testicular level (cortisol → Leydig cell testosterone synthesis is inversely correlated). By reducing chronic cortisol elevation, ashwagandha appears to partially restore testosterone production suppressed by HPA hyperactivity — rather than directly stimulating androgen synthesis. This explains why the testosterone effect is primarily observed in stressed or high-training-load populations, not in individuals with normal baseline cortisol.
| Study | Population / Design | Extract / Dose | Key Findings |
|---|---|---|---|
| Chandrasekhar et al. 2012 (Indian J Psychol Med) | N=64 chronically stressed adults, 60-day RCT | KSM-66 300mg BID (600mg/day) | −27.9% serum cortisol; −44% PSS; −75.6% DASS anxiety; no serious AEs |
| Wankhede et al. 2015 (J Int Soc Sports Nutr) | N=57 resistance-trained men, 8-week RCT | KSM-66 300mg BID (600mg/day) | +17% testosterone; +18.8kg bench press; +18.3% VO₂max; reduced DOMS |
| Auddy et al. 2008 (J Am Nutraceut Assoc) | N=98 chronically stressed adults, 60-day RCT | Sensoril (root+leaf extract) 125–500mg/day | Dose-dependent cortisol reduction (−24.2% at 500mg); improved CRP, blood pressure, fasting glucose |
| Pratte et al. 2014 (J Altern Complement Med) | N=98, 60-day RCT | Ashwagandha root powder 300mg BID | Reduced PSS and cortisol; effect smaller than KSM-66 extract, consistent with lower withanolide content of unextracted root powder |
| Gopukumar et al. 2021 (Evidence-Based Complement Altern Med) | N=50 adults, 8-week RCT | KSM-66 300mg BID | Improved cognitive function (MoCA, Trail Making Test); significant vs placebo; consistent with GABA-A and neuroprotective mechanisms |
Extract Standardization: Why Product Selection Matters More Than with Most Supplements
Ashwagandha is a category where the gap between clinical evidence and what consumers actually purchase is especially wide. The RCT evidence is almost entirely from two proprietary extracts:
- KSM-66 (Ixoreal Biomed): root-only extract, standardized to ≥5% withanolides by HPLC; produced via milk decoction extraction (traditional Ayurvedic processing preserving lipophilic withanolides); used in Chandrasekhar 2012, Wankhede 2015, and most high-quality subsequent trials
- Sensoril (Natreon): root + leaf extract, standardized to ≥10% withanolides; higher withanolide concentration but different profile (leaf extracts contain withaferin A at higher levels, which has different receptor targets than root-predominant withanolides)
Raw ashwagandha root powder contains 0.1–0.5% withanolides — 10–50× less than KSM-66. A product selling "500mg ashwagandha powder" may contain the withanolide equivalent of 10–50mg KSM-66. This explains why studies using standardized extracts consistently show cortisol effects while studies using root powder show smaller, less consistent results.
Evidence-Based Ashwagandha Protocol
- Extract standard: KSM-66 or Sensoril exclusively. Verify the supplement label states the branded extract name — not just "ashwagandha root extract" or "standardized to withanolides" (which can be self-claimed). KSM-66 is the better-studied root-only extract matching the Chandrasekhar RCT.
- Dose: 300mg KSM-66 twice daily (600mg/day) to match the primary clinical trial. Once-daily 600mg dosing is likely equivalent — withanolide half-life supports once-daily use. Some protocols use 300mg/day as a maintenance dose after an initial 600mg loading period.
- Timing: Most protocols take one dose with morning meal, one with evening meal. Taking the evening dose closer to bedtime may leverage the mild sedative/GABA-A effect for sleep quality improvement (a secondary endpoint improved in multiple ashwagandha trials).
- Timeline for effects: Cortisol reduction is measurable at 30 days but maximal benefit in trials is reported at 60 days. Sleep quality improvement is often reported within 1–2 weeks. Testosterone effects require ≥8 weeks of consistent use.
- Who benefits most: High-stress individuals with elevated morning cortisol, athletes with high training loads and recovery deficits, individuals with stress-related sleep disruption. Ashwagandha's effects are strongest where the HPA axis is most dysregulated — individuals with normal baseline cortisol and minimal stress show smaller objective improvements.
- Thyroid interaction: Ashwagandha modestly increases T3 and T4 in some studies. Individuals on thyroid medication should monitor thyroid function if starting ashwagandha supplementation. Autoimmune thyroid conditions (Hashimoto's) may theoretically be affected by immune-modulating withanolides.
Recommended Products (Amazon)
Look for "KSM-66" explicitly labeled on the bottle — not just "ashwagandha extract." Well-regarded KSM-66 products from Jarrow Formulas, NOW Foods (KSM-66), Thorne, and Pure Encapsulations are third-party tested. Avoid products that only state "standardized to withanolides" without identifying the proprietary extract — this is often self-certification of unknown accuracy.